Closed System Transfer Device Market Size, Share & Trends Analysis Report By Product (Closed Vial Access Devices, Closed Syringe Safety Devices, Closed Bag/Line Access Devices), By Applications (Hospital, Clinic), By End Use, By Region, and Segment Forecasts - 2035

Closed System Transfer Device Market Overview

closed system transfer device market size was valued at USD 804.5 million in 2025 and is poised to grow from USD 953.33 million in 2026 to USD 4407.68 million by 2035, growing at a CAGR of 18.5% during the forecast period (2026-2035).

The Closed System Transfer Device Market is expanding rapidly as healthcare institutions strengthen protection against occupational exposure to hazardous drugs during preparation, transfer, administration, and disposal. Closed Vial Access Devices, Closed Syringe Safety Devices, and Closed Bag/Line Access Devices are increasingly incorporated into oncology pharmacies, infusion centers, hospital pharmacies, and specialized treatment facilities. Demand is particularly strong where antineoplastic and other hazardous medications require repeated handling by pharmacists and nurses. Modern systems are designed around mechanically closed connections, pressure-equalization mechanisms, needle-free interfaces, and contamination-control features that reduce leakage during drug transfer. Hospitals are also standardizing hazardous-drug workflows across multiple departments rather than limiting protection to pharmacy preparation areas. With the market advancing at 18.5% CAGR through 2035, adoption is expected to increase significantly as worker-safety practices, oncology treatment volumes, and institutional protocols become more stringent.

The U.S. represents a major market for closed system transfer devices because hospitals, oncology centers, ambulatory treatment facilities, and specialty pharmacies increasingly prioritize hazardous-drug containment. Healthcare workers may handle hazardous medications several times during 1 treatment cycle, creating multiple opportunities for accidental exposure without appropriate engineering controls. Large hospitals are increasingly implementing standardized CSTD protocols covering pharmacy compounding and bedside administration, while smaller clinics are adopting simpler device configurations for outpatient chemotherapy. Closed Vial Access Devices remain especially important during preparation, whereas Closed Syringe Safety Devices and Closed Bag/Line Access Devices support safer transfer and administration. Continued growth in cancer treatment, specialty infusion services, and healthcare worker protection is expected to sustain strong U.S. adoption during the 2026-2035 period.

• 

  Download Free sample to learn more about this report.

Key Findings

• Leading Product Type: Closed Vial Access Devices are expected to hold the largest share, supported by widespread pharmacy use and frequent vial-based hazardous-drug preparation across oncology and specialty treatment workflows.
• Leading Application: Hospital is expected to dominate application demand with approximately 72% share, supported by centralized pharmacies, oncology departments, infusion units, and higher hazardous-drug handling volumes.
• Leading Region: North America is expected to lead with approximately 45% share as hospitals increasingly standardize hazardous-drug handling procedures and deploy closed transfer systems across pharmacy and administration workflows.
• Fastest Growing Region: Asia Pacific is projected to expand fastest as oncology infrastructure and hospital safety investment increase, with regional growth expected to exceed the global 18.5% CAGR.
• Technology Trend: Needle-free and mechanically closed connector designs are gaining adoption as hospitals seek systems capable of maintaining a sealed drug-transfer pathway through multiple connection and disconnection cycles.
• Market Driver: Rising occupational safety requirements are accelerating adoption because hazardous-drug preparation can involve several transfer steps during 1 medication cycle, increasing the importance of closed handling.
• Competitive Landscape: Leading suppliers are expanding integrated portfolios across all 3 supplied device categories, enabling hospitals to standardize hazardous-drug handling from vial access through final administration.
• Future Outlook: Broader use outside centralized oncology pharmacies will support long-term expansion as the market approaches USD 4407.68 million by 2035 through hospital and clinic adoption.

Latest Trends

The Closed System Transfer Device Market is increasingly shifting toward integrated systems that cover hazardous-drug handling from preparation through administration. Healthcare institutions are moving away from isolated device use and toward standardized workflows that combine Closed Vial Access Devices, Closed Syringe Safety Devices, and Closed Bag/Line Access Devices. This approach reduces inconsistencies between pharmacy and nursing procedures and supports safer transitions during drug preparation and infusion. Needle-free connections, pressure-management mechanisms, dry-disconnection designs, and simplified locking systems are receiving greater attention because they reduce unnecessary handling steps. Hospitals with multiple oncology treatment locations are also seeking compatible platforms that can be deployed across more than 1 department without extensive workflow modification.

Another important trend is increasing adoption within outpatient and ambulatory treatment environments. Historically, CSTD demand was concentrated primarily in large hospital oncology pharmacies, but specialized clinics and infusion centers are becoming more important as cancer therapy increasingly shifts toward outpatient care. Device manufacturers are responding with compact components, easier connection mechanisms, and systems designed to minimize preparation complexity. Clinics with limited staffing particularly value devices that can be integrated into existing workflows without extensive additional training. Digital education, standardized operating procedures, and competency programs are also becoming more common as institutions seek consistent hazardous-drug handling across different user groups. These trends are supporting the market's strong 18.5% CAGR over the 2026-2035 forecast period.

Market Dynamics

Driver

""Growing emphasis on hazardous-drug safety is accelerating CSTD adoption.""

The strongest driver of the Closed System Transfer Device Market is increasing attention to occupational protection for pharmacists, nurses, technicians, and other healthcare personnel handling hazardous medications. Oncology treatment frequently involves repeated vial access, syringe transfer, bag preparation, and administration, creating several exposure points during 1 treatment workflow. CSTDs are designed to reduce the escape of hazardous drug contaminants while preventing environmental contaminants from entering the system. Hospitals increasingly incorporate these devices into formal hazardous-drug handling policies rather than relying only on personal protective equipment. The growing number of oncology procedures and specialty infusions is expanding the installed base of compatible devices. As healthcare institutions increase investments in safer medication workflows, demand for all 3 supplied CSTD categories is expected to remain strong through 2035.

Restraint

""Higher per-procedure costs can limit adoption in budget-sensitive facilities.""

Cost remains an important restraint because closed system transfer devices add disposable components to hazardous-drug preparation and administration workflows. A single treatment can require more than 1 specialized connector depending on the number of vials, syringes, bags, and infusion-line interfaces involved. This can increase supply expenditure for hospitals handling large oncology volumes. Smaller clinics may be particularly sensitive to recurring device costs when patient throughput is limited. Hospitals must also evaluate compatibility with existing syringes, vials, infusion sets, and pharmacy equipment before standardizing a platform. Training requirements create additional operational effort because pharmacists and nurses need consistent procedures for correct connection and disconnection. These factors can slow adoption despite the market's projected 18.5% CAGR.

Opportunity

""Outpatient oncology and specialty infusion centers create significant expansion potential.""

The expansion of outpatient cancer treatment creates a major opportunity for the Closed System Transfer Device Market. More chemotherapy, targeted therapies, and specialty infusions are being administered outside traditional inpatient environments, increasing the number of clinics that handle hazardous medications. These facilities require solutions that are compact, intuitive, and compatible with existing infusion workflows. Manufacturers that provide complete systems covering vial access, syringe transfer, and bag or line connection can address multiple stages of the medication process with 1 coordinated platform. Emerging healthcare markets also offer opportunities as hospitals increase oncology capacity and introduce more standardized worker-safety procedures. Asia Pacific is particularly attractive because regional adoption is expected to grow faster than the worldwide 18.5% rate.

Challenge

""Workflow compatibility and consistent staff use remain major implementation challenges.""

A key challenge in the Closed System Transfer Device Market is maintaining correct and consistent use across different clinical environments. Hospitals may involve pharmacists, technicians, nurses, and infusion specialists in the same hazardous-drug workflow, meaning several user groups must follow identical connection and disconnection procedures. Even a system designed around 3 core device categories can require different handling steps depending on the medication container and administration method. Compatibility with vial dimensions, syringe formats, infusion bags, and tubing configurations also affects implementation. Healthcare institutions therefore need standardized training, competency checks, and purchasing policies to avoid mixing incompatible components. Manufacturers that simplify connections and reduce the number of procedural steps are likely to achieve stronger adoption as hospitals pursue safer and more efficient hazardous-drug handling.

• 

  Download Free sample to learn more about this report.

Segmentation Analysis

By Types

Closed Vial Access Devices: Closed Vial Access Devices hold the largest share of the Closed System Transfer Device Market at approximately 46%, supported by widespread use during hazardous-drug preparation in hospital pharmacies and oncology treatment environments. These devices are designed to create a closed pathway when medication is withdrawn from or introduced into a vial, reducing the possibility of drug leakage and environmental contamination. Their importance is particularly high in cancer treatment, where hazardous medications may be prepared several times during 1 working shift. Hospitals increasingly standardize vial access components as the first stage of a broader CSTD workflow. Growing adoption of centralized pharmacy compounding and stricter worker-safety practices are strengthening demand. Manufacturers are also improving connection security, pressure equalization, and ease of handling to reduce user error. As healthcare institutions expand oncology services, Closed Vial Access Devices are expected to maintain their leading position throughout the forecast period.

Closed Syringe Safety Devices: Closed Syringe Safety Devices account for approximately 31% of the market and are widely used to transfer hazardous drugs between vials, syringes, bags, and administration systems. These products help maintain a closed fluid pathway during preparation and transfer, reducing the risk of leakage or aerosol exposure. Demand is particularly strong in hospital pharmacies and oncology units where multiple syringe transfers may occur during 1 treatment procedure. Modern devices increasingly incorporate needle-free designs, locking connectors, and simplified attachment mechanisms to improve workflow efficiency. Closed Syringe Safety Devices are also becoming more relevant in outpatient clinics as hazardous-drug administration expands beyond large hospitals. Their ability to support safer transfer while fitting into existing syringe-based workflows makes them an important component of integrated CSTD systems.

Closed Bag/Line Access Devices: Closed Bag/Line Access Devices represent approximately 23% of the Closed System Transfer Device Market and are increasingly used during the final stages of hazardous-drug preparation and administration. These devices help create a closed connection between drug containers, infusion bags, and administration lines, supporting safer handling at the bedside or infusion chair. Their adoption is growing as hospitals extend CSTD protocols beyond pharmacy preparation into nursing and administration workflows. Oncology departments may use more than 1 bag or line connection during a treatment session, making compatibility and secure locking mechanisms important. Manufacturers are focusing on designs that reduce disconnection risk and simplify workflow transitions. As more institutions adopt end-to-end hazardous-drug safety programs, Closed Bag/Line Access Devices are expected to gain a larger role in integrated CSTD deployment.

By Applications

Hospital: Hospital applications account for approximately 72% of the Closed System Transfer Device Market, making this the dominant end-use segment. Hospitals handle higher volumes of hazardous medications through centralized pharmacies, oncology departments, infusion units, and specialty treatment areas, creating strong demand for closed transfer systems. Large facilities often deploy all 3 supplied CSTD categories to protect staff during drug preparation, transfer, and administration. Hospitals also tend to have formal hazardous-drug policies, structured training programs, and larger procurement budgets than smaller treatment facilities. Repeated drug handling across multiple departments increases the importance of standardized systems that can be used consistently by pharmacists, technicians, and nurses. Continued expansion of oncology treatment volumes and stronger occupational safety practices are expected to maintain hospitals as the leading application through 2035.

Clinic: Clinic applications represent approximately 28% of the Closed System Transfer Device Market and are becoming increasingly important as chemotherapy and specialty infusion services shift toward outpatient care. Clinics generally handle lower patient volumes than large hospitals but still require effective protection when preparing and administering hazardous medications. Closed Vial Access Devices and Closed Syringe Safety Devices are particularly relevant because they can be integrated into compact pharmacy or treatment workflows without extensive equipment changes. Closed Bag/Line Access Devices are also gaining adoption as clinics standardize safe administration procedures. Smaller facilities tend to prioritize easy-to-use systems with fewer procedural steps because staffing levels are often more limited. As outpatient oncology and specialty infusion services continue expanding, clinic demand is expected to grow faster than its current market share suggests.

• 

  Download Free sampleto learn more about this report.

Regional Outlook

North America

North America accounts for approximately 45% of the Closed System Transfer Device Market and remains the leading region due to strong adoption across hospital pharmacies, oncology centers, infusion clinics, and specialty treatment facilities. The U.S. represents the largest contributor because healthcare institutions increasingly standardize hazardous-drug handling procedures across preparation and administration. Closed Vial Access Devices are widely used in pharmacy environments, while Closed Syringe Safety Devices and Closed Bag/Line Access Devices support safer drug transfer and infusion workflows. Regional hospitals typically operate more structured occupational-safety programs and have greater access to specialized oncology infrastructure. Growing cancer treatment volumes and increasing use of hazardous medications are reinforcing demand for closed transfer technologies across both inpatient and outpatient settings.

The region also benefits from strong manufacturer presence, established distribution networks, and greater awareness of occupational exposure risks. Large healthcare systems increasingly evaluate CSTD platforms as integrated solutions rather than individual components, encouraging demand across all 3 supplied product types. Clinics are also becoming more important as outpatient chemotherapy and specialty infusion services expand. Standardized staff training and compatibility with existing medication-delivery systems are becoming important purchasing factors. With the overall market growing at 18.5% CAGR through 2035, North America is expected to retain a major share even as faster adoption occurs in emerging healthcare markets.

Europe

Europe represents approximately 27% of the Closed System Transfer Device Market, supported by advanced hospital infrastructure, strong oncology services, and increasing emphasis on healthcare worker protection. Germany, France, the United Kingdom, Italy, Spain, and Nordic countries contribute significantly to regional demand. Hospitals remain the primary application because centralized pharmacies and oncology units handle substantial volumes of hazardous medications. Closed Vial Access Devices are especially important during drug preparation, while syringe and bag-line systems are increasingly incorporated into end-to-end safety workflows. Growing awareness of occupational contamination is encouraging healthcare institutions to adopt more structured procedures for handling antineoplastic and other hazardous drugs.

Regional demand is also supported by the expansion of ambulatory oncology and specialty infusion facilities. Clinics are increasingly adopting simplified CSTD platforms that can be integrated into smaller treatment environments without major workflow changes. European healthcare providers generally prioritize device compatibility, reliability, ease of training, and low procedural complexity. Manufacturers are responding with systems designed to reduce connection steps and improve usability across multiple staff groups. As oncology services expand and institutions strengthen hazardous-drug handling protocols, Europe is expected to maintain steady growth throughout the forecast period.

Asia Pacific

Asia Pacific holds approximately 20% of the Closed System Transfer Device Market and is expected to be the fastest-growing regional market during the forecast period. Growth is being driven by expanding oncology infrastructure, rising cancer treatment volumes, hospital modernization, and increasing awareness of occupational exposure risks. China, Japan, South Korea, India, and Australia are among the most important markets. Large hospitals are beginning to adopt more standardized hazardous-drug handling systems, while specialty oncology centers are increasing demand for closed vial, syringe, and bag-line access products. Expanding pharmaceutical and healthcare infrastructure is also improving product availability across major metropolitan areas.

Regional market development is still uneven, creating significant opportunities for manufacturers and distributors. Premium hospitals in developed Asian markets already use more advanced safety systems, while adoption in emerging markets is increasing from a lower base. Training, product affordability, and local distribution remain important factors influencing procurement. Clinics are becoming more relevant as outpatient oncology services expand across urban centers. With growth expected to exceed the global 18.5% CAGR, Asia Pacific is likely to increase its share substantially through 2035 as worker-safety practices become more standardized.

Latin America

Latin America accounts for approximately 5% of the Closed System Transfer Device Market, with Brazil and Mexico representing the largest regional demand centers. Adoption is concentrated in major hospitals, oncology centers, and specialized private healthcare facilities. Hospitals handling high volumes of chemotherapy are increasingly introducing closed transfer systems to reduce occupational exposure during drug preparation and administration. Closed Vial Access Devices generally represent the most common entry point for adoption, while syringe and bag-line components are added as institutions develop broader safety protocols. Demand is growing gradually as healthcare providers invest in oncology infrastructure and staff-protection measures.

Regional growth is influenced by budget constraints, uneven healthcare infrastructure, and varying access to specialized medical devices. Private hospitals and larger urban facilities tend to adopt CSTD systems earlier than smaller public institutions. Distributors play an important role in providing product training, technical support, and supply continuity. Clinics offering outpatient chemotherapy are also creating incremental demand as treatment delivery shifts away from inpatient settings. Although Latin America currently represents a smaller market share, increasing cancer-care capacity is expected to support steady expansion through 2035.

Middle East & Africa

Middle East & Africa represents approximately 3% of the Closed System Transfer Device Market. Demand is concentrated in Gulf countries, South Africa, and selected urban healthcare centers where oncology treatment infrastructure is relatively advanced. Hospitals remain the main application because they handle larger volumes of hazardous medications and have stronger procurement capabilities. Closed Vial Access Devices are commonly prioritized first, while Closed Syringe Safety Devices and Closed Bag/Line Access Devices are gradually adopted as institutions develop more comprehensive hazardous-drug protocols. Growth is supported by expanding cancer treatment capacity and broader investment in hospital modernization.

Regional adoption remains limited by cost sensitivity, inconsistent access to specialized devices, and variable staff training. International manufacturers typically rely on distributors to reach hospitals and clinics across the region. Gulf healthcare systems are expected to provide the strongest opportunities because of continued investment in premium oncology facilities and specialized medical services. African demand is likely to remain concentrated in major private and teaching hospitals. As hazardous-drug handling practices become more standardized, Middle East & Africa is expected to generate gradual but consistent market growth.

List of Top Closed System Transfer Device Companies

• BD Medical, Inc
• Equashield, LLC
• ICU Medical, Inc
• Teva Medical Ltd
• Corvida Medical
• B. Braun

Top 2 Companies Market Share

BD Medical, Inc: BD Medical, Inc is estimated to hold approximately 29% of the Closed System Transfer Device Market, supported by broad adoption across hospital pharmacies, oncology treatment centers, and integrated hazardous-drug handling workflows. Its product reach across vial, syringe, and administration-related safety solutions strengthens its competitive position.

Equashield, LLC: Equashield, LLC is estimated to account for approximately 21% of the market, supported by strong specialization in closed transfer technologies and growing adoption among hospitals and outpatient oncology facilities. The company's integrated approach across multiple handling stages supports broader institutional standardization.

Investment Analysis

Investment in the Closed System Transfer Device Market is increasingly directed toward hazardous-drug safety, oncology infrastructure, automated compounding compatibility, and standardized medication-transfer systems. The market is expanding at 18.5% CAGR through 2035, encouraging manufacturers to strengthen product portfolios covering preparation and administration workflows. Hospitals are investing in systems that connect Closed Vial Access Devices, Closed Syringe Safety Devices, and Closed Bag/Line Access Devices within a single safety protocol. This approach can reduce the need to manage multiple incompatible components and simplify staff training. Investment opportunities are also expanding in outpatient oncology because chemotherapy and specialty infusions are increasingly performed outside traditional inpatient environments. Manufacturers that provide compact devices, secure connection mechanisms, and simplified workflows can address the growing requirements of both large hospitals and smaller clinics.

Asia Pacific is becoming an important investment destination as oncology capacity, hospital infrastructure, and healthcare worker protection programs expand. North America continues to attract significant product-development spending because healthcare institutions increasingly require advanced hazardous-drug containment throughout preparation and administration. Suppliers are also investing in manufacturing efficiency and distribution capacity to support greater recurring demand for disposable components. Closed transfer systems typically require multiple components during a single treatment workflow, making reliable supply particularly important for high-volume oncology facilities. Partnerships with hospital systems, distributors, infusion networks, and specialty pharmacies can help manufacturers expand adoption more efficiently. Continued product standardization and stronger occupational-safety awareness are expected to maintain attractive investment conditions throughout the 2026-2035 forecast period.

New Product Development

New product development in the Closed System Transfer Device Market is focused on improved ergonomics, secure connections, reduced handling steps, and stronger containment throughout hazardous-drug transfer. Manufacturers are developing systems that support both preparation and administration rather than protecting only 1 stage of the workflow. Newer designs increasingly incorporate self-sealing interfaces, needle-free connections, pressure-management mechanisms, and components that maintain a closed pathway during connection and disconnection. BD's PhaSeal Optima platform represents this direction, using a second-generation design intended to improve hazardous-drug transfer while retaining physical barrier technology. The platform includes several interconnected components, supporting preparation and administration within an integrated CSTD workflow. 

Product developers are also prioritizing usability because hazardous drugs may pass through 3 or more handling stages before reaching the patient. Reducing unnecessary connection steps can help improve workflow consistency among pharmacists, technicians, and nurses. Manufacturers are therefore designing vial protectors, syringe-related connectors, infusion adapters, and administration components that operate as coordinated systems. Improved ergonomics are particularly important for hospitals processing large numbers of oncology preparations during each shift. Product innovation is also extending toward compatibility with automated compounding, standardized infusion systems, and outpatient treatment environments. As the market expands at 18.5% CAGR, manufacturers that combine containment performance with simpler operation are expected to gain stronger adoption.

Five Recent Developments

• November 2024: BD introduced its PhaSeal Optima System in Japan, expanding access to a next-generation closed system transfer platform designed for hazardous-drug preparation with improved usability and retained physical barrier protection. 
• December 2024: Healthcare providers continued expanding integrated CSTD protocols across pharmacy and administration workflows, increasing adoption of systems that connect vial, syringe, and infusion components rather than protecting only 1 transfer stage.
• May 2025: Product development increasingly emphasized needle-free and self-sealing connection mechanisms as hospitals sought to simplify hazardous-drug handling and reduce the number of manual connection steps required during oncology preparation.
• November 2025: Manufacturers increased focus on outpatient-compatible CSTD configurations as specialty infusion clinics expanded hazardous-drug administration outside traditional inpatient oncology environments, strengthening demand for compact and simplified systems.
• July 2026: BD planned depletion of selected original PhaSeal and SmartSite VialShield products in the U.S. around July 1, 2026 as customers transition toward the newer PhaSeal Optima System. 

Report Coverage

The Closed System Transfer Device Market report evaluates industry development across Closed Vial Access Devices, Closed Syringe Safety Devices, and Closed Bag/Line Access Devices. Application analysis covers Hospital and Clinic settings, reflecting the principal environments in which hazardous medications are prepared and administered. The report examines market trends, growth drivers, restraints, opportunities, implementation challenges, segmentation patterns, regional demand, competitive positioning, investment activity, and product innovation. Particular attention is given to oncology expansion, healthcare worker protection, outpatient infusion growth, needle-free connections, and standardized hazardous-drug workflows. The forecast extends through 2035, with the market expected to expand at a CAGR of 18.5% from 2026 onward.

The competitive assessment covers BD Medical, Inc, Equashield, LLC, ICU Medical, Inc, Teva Medical Ltd, Corvida Medical, and B. Braun. Regional coverage includes North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, with analysis of differences in hospital infrastructure, oncology capacity, occupational-safety adoption, and outpatient treatment development. The report also examines developments between 2024 and 2026, including next-generation transfer systems, improved connection mechanisms, broader administration protection, and transitions toward integrated platforms. Together, these areas provide a structured assessment of how demand for closed hazardous-drug transfer technology is evolving across hospitals and clinics worldwide.